Management of direct-acting antiviral agent failures

Buti, María; Riveiro‐Barciela, Mar; Esteban, Rafael

doi:10.1016/j.jhep.2015.08.010

Cited by 75 publications

(59 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bu suşların TVR ve BOC arasında çapraz dirence neden olduğu da bildirilmiştir. Dirençli varyantların sıklığı ve çeşitliliğinin infekte eden HCV subtipiyle ilişkili olduğu bulunmuştur (141). SMV gibi ikinci kuşak proteaz inhibitörlerinin antiviral etkinliği birinci kuşak proteaz inhibitörlerine göre daha güçlü olmakla birlikte, bu ilaçların genetik bariyerleri de düşüktür.…”

Section: Doğrudan Etkili Antiviral Direncinin Klinik Yönetimiunclassified

“…Özellikle SMV içeren bir rejimle ikinci tedavi verilecekse, Q80K mutasyonu araş-tırılmalı; önceki tedavide kullanılan ilaçlarla çapraz direnci olan bir ilaç yeniden tedavide yeğlenmemelidir (141). Yine de literatürde bu konudaki öneriler kesinlik kazanmamış olup, DEA ilaçlarla tedavi deneyimleri arttıkça daha net veriler oluşacaktır.…”

Section: Doğrudan Etkili Antiviral Direncinin Klinik Yönetimiunclassified

“…DEA kombinasyon rejimleriyle başarısızlık, tedavi deneyimli ve genotip 1a ve genotip 3 HCV infeksiyonlu sirotik hastalarda, ilaca dirençli suşların ortaya çıkması nedeniyle görülmekteyken, sirotik olmayan hastalardaki başarısız-lık daha çok 12 haftadan kısa tedavi süreleriyle ilişkilidir. Bu tedavilerle virolojik kırılma hemen hemen hiç görülmemekte olup, varsa tedavi uyumsuzluğu nedeniyle olmaktadır (141). DEA tedavi rejimleri verilen hastalarla ilgili gerçek yaşam verileri gelecekte uygulanacak stratejilerin belirlenmesinde esas olacaktır.…”

Section: Doğrudan Etkili Antiviral Direncinin Klinik Yönetimiunclassified

See 2 more Smart Citations

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2017 Update

Aygen¹,

Demirtürk²,

Türker³

et al. 2017

Klimik Dergisi

View full text Add to dashboard Cite

show abstract

Section: Doğrudan Etkili Antiviral Direncinin Klinik Yönetimiunclassified

See 1 more Smart Citation

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2017 Update

Aygen¹,

Demirtürk²,

Türker³

et al. 2017

Klimik Dergisi

View full text Add to dashboard Cite

show abstract

“…However, with a few exceptions, HCV drug resistance testing is not recommended in naïve patients, because SVR rates were not affected by the presence of baseline NS3/4A or NS5A RAVs [45]. Moreover, the majority of treatment failures with DAAs are usually related to relapse rather than on-treatment viral breakthrough [48].…”

Section: Resistance To Daasmentioning

confidence: 99%

A Brief Update on the Treatment of Hepatitis C

Austria¹,

Ninčević²,

Wu³

2017

Update on Hepatitis C

View full text Add to dashboard Cite

Hepatitis C virus was discovered nearly 30 years ago, and for the first two decades, treatment was limited to agents with low response rates and substantial side effects. Since the introduction of direct-acting antivirals, there have been rapid advances made toward even higher sustained virologic responses (SVRs) and fewer side effects. This chapter provides a review of the newer agents for treatment of hepatitis C and highlights special populations, including those coinfected with HIV or hepatitis B, previously treated patients, and post-liver transplant patients.

show abstract

“…Some authors highlight the importance of resistance testing in patients who fail multiple DAAs for deciding retreatment and selecting salvage therapy [90, 108, 109]. More recently, Sarrazin encourages also the baseline testing in patients treated with a combination of a first generation NS3/4A protease and NS5A inhibitor with a low barrier of resistance.…”

Section: Do We Need Daas Resistance Testing In the Future?mentioning

confidence: 99%

State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

Trucchi

Orsi

Alicino

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

Hepatitis C virus (HCV) still represents a major public health threat, with a dramatic burden from both epidemiological and clinical points of view. New generation of direct-acting antiviral agents (DAAs) has been recently introduced in clinical practice promising to cure HCV and to overcome the issues related to the interferon-based therapies. However, the emergence of drug resistance and the suboptimal activity of DAAs therapies against diverse HCV genotypes have been observed, determining treatment failure and hampering an effective control of HCV spread worldwide. Moreover, these treatments remain poorly accessible, particularly in low-income countries. Finally, effective screening strategy is crucial to early identifying and treating all HCV chronically infected patients. For all these reasons, even though new drugs may contribute to impacting HCV spread worldwide a preventive HCV vaccine remains a cornerstone in the road to significantly reduce the HCV spread globally, with the ultimate goal of its eradication. Advances in molecular vaccinology, together with a strong financial, political, and societal support, will enable reaching this fundamental success in the coming years. In this comprehensive review, the state of the art about these major topics in the fight against HCV and the future of research in these fields are discussed.

show abstract

Management of direct-acting antiviral agent failures

Cited by 75 publications

References 79 publications

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2017 Update

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2017 Update

A Brief Update on the Treatment of Hepatitis C

State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

Contact Info

Product

Resources

About